Immunocytochemistry/ Immunofluorescence: CHREBP Antibody (2D9NB) [NBP2-44307] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells ...read more
Immunohistochemistry-Paraffin: CHREBP Antibody (2D9NB) [NBP2-44307] - Analysis of a FFPE tissue section of human hepatocellular carcinoma using 1:200 dilution of CHREBP antibody (clone 2D9NB). The antibody generated a ...read more
Immunohistochemistry-Paraffin: CHREBP Antibody (2D9NB) [NBP2-44307] - Analysis of a FFPE tissue section of normal human kidney using 1:200 dilution of CHREBP antibody (clone 2D9NB). The antibody generated a diffused to ...read more
Mouse reactivity reported in scientific literature (PMID: 31289120).
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
Protein G purified
Alternate Names for CHREBP Antibody (2D9NB)
CHREBPcarbohydrate-responsive element-binding protein
Class D basic helix-loop-helix protein 14
MIOWS basic-helix-loop-helix leucine zipper protein
MLX interacting protein-like
MONDOBWilliams-Beuren syndrome chromosomal region 14 protein
WBSCR14Williams-Beuren syndrome chromosome region 14 protein 1
Williams Beuren syndrome chromosome region 14
Williams-Beuren syndrome chromosome region 14 protein 2
WS-bHLHbHLHd14carbohydrate response element binding protein
Carbohydrate response element-binding protein (ChREBP) is a glucose sensitive basic helix-loop-helix/leucine zipper transcription factor which heterodimerise with MLX and binds to carbohydrate response element (ChoRE) on DNA for the induction genes involved in glycolysis, de novo lipogenesis (DNL), and fatty acid desaturation. Some of the target genes of ChREBP are glucokinase (GCK), fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), pyruvate kinase/liver type pyruvate kinase (PK1/ PKLR), delta-9-desaturase (SCD/SCD1) etc. ChREBP is expressed as alpha and beta alternatively spliced isoforms, and among these two isoforms, the alpha-isoform is activated in a glucose-dependent manner. ChREBP is expressed in the cytoplasm and nuclei of a number of mammalian tissues, with high levels found in liver, skeletal muscle, white/brown adipose, heart, kidney, cerebellum and intestine. Glucose stimulates ChREBP transcriptional expression and activates the transactivity of ChREBP protein. It is activated independent of insulin and recent findings have suggested that together with its binding partner Mlx, ChREBP implicates in metabolic processes, insulin signaling related pathways, and also tumorigenesis/cancers. Also, increased hepatic ChREBP expression has been suggested to result in development of non-alcoholic fatty liver disease (NAFLD) and obesity through the conversion of carbohydrates into triglycerides (de novo lipogenesis).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CHREBP Antibody (2D9NB) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.